世界のハイスループットスクリーニング（高速大量スクリーニング）市場動向及び予測（～2018）...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 19)
1.1 Objectives of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Secondary Sources
1.6.2 Primary Sources
1.6.3 Market Size Estimation
1.6.4 Market Share
1.6.5 Key Data Points From Secondary Sources
1.6.6 Key Data Points From Primary Sources
1.6.7 Assumptions

2 Executive Summary (Page No. – 36)

3 Premium Insights (Page No. – 40)
3.1 HTS Market – A Sub-Segment of Drug Discovery Market
3.2 Global HTS Market
3.3 Market Dynamics
3.4 Geographic Analysis & HTS Technologies Market
3.5 Technology Market
3.6 End-User Analysis
3.7 Competitive Analysis

4 Market Overview (Page No. – 47)
4.1 Introduction
4.2 Technology Evolution
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Adoption of Open Innovation Models By Pharmaceutical Companies to Increase The Use of HTS
4.4.1.2 Increasing Drug Discovery Initiatives By Academic and Government Institutions to Boost The Demand for HTS Products
4.4.1.3 Increasing Capital Investments in HTS Technology By Organizations Lead to The Growth of HTS
4.4.1.4 Technological Advancements in Research Leading to Large Potential Candidates for Screening Will Help HTS
4.4.1.5 Increase in The Number of Outsourced Drug Discovery Services Will Propel The HTS Market
4.4.2 Restraints
4.4.2.1 The Capital-Intensive Nature of HTS Will Hamper The Growth of This Market
4.4.2.2 Assay Development for HTS Becoming Difficult for New Target Classes
4.4.3 Opportunities
4.4.3.1 Growing Asian Market to Boost The HTS Market
4.4.3.2 High Throughput Cellular Microarrays Increasingly Being Used in toxicology and Stem Cell Research, Thus Prompting Its Growth
4.4.3.3 Growth of Contract Research Organizations (Cros) in Emerging Countries to Bolster The HTS Market
4.4.3.4 Label-Free Technology Emerging As A Valuable Tool for Drug Discovery
4.5 Trends
4.5.1 Label-Free Method Gaining Importance in HTS Labs
4.5.2 HTS Techniques Increasingly Being Used in The Field of Toxicology
4.5.3 Automation & Miniaturization of HTS Techniques
4.6 Strategic Benchmarking
4.6.1 New Product Launches
4.6.1.1 Agilent Technologies Introduced The Rapidfire 365 High Throughput Mass Spectrometry System
4.6.1.2 Perkinelmer Introduced The Janus Biotx Pro Automated Workstation
4.6.1.3 Beckman Coulter Introduced The Navios Flow Cytometry System
4.6.1.4 Sigma-Aldrich Introduced The Compozr Transporter Knockout Human Cell Lines in Plate format
4.6.1.5 Tecan Group Introduced Dako Omnis
4.6.2 Technology Integration
4.6.2.1 Collaboration Between Agilent & Baylor College of Medicine’s Medical Genetics Laboratories
4.6.2.2 Collaboration Between Perkinelmer & The National Center for Drug Screening (Ncds)
4.6.2.3 Partnership of Beckman Coulter With Illumina
4.6.2.4 Agreement of Sigma-Aldrich Corporation With Alphagenix
4.6.2.5 Agreement of Tecan Group With Tap Biosystems
4.7 Value Chain Analysis
4.8 Porter’s Five Forces Analysis
4.8.1 Threat From New Entrants
4.8.2 Threat From Substitutes
4.8.3 Bargaining Power of Buyers
4.8.4 Bargaining Power of Suppliers
4.8.5 Competitive Rivalry Among Existing Players
4.9 Key Player Analysis

5 By Technology (Page No. – 72)
5.1 Introduction
5.2 Cell-Based Assays
5.2.1 Cell-Based Assays Are Used in More Than 50% of HTS Assays
5.3 Ultra High Throughput Screening (UHTS)
5.3.1 UHTS Increasers The Number of Potential Drug Candidates Tested Per Day
5.4 Lab-On-A-Chip (Loac)
5.4.1 Loac Market to Grow At A High Pace
5.5 Label-Free Technology
5.5.1 Label-Free Technology to Grow At The Fastest Pace in HTS Market
5.6 Bioinformatics
5.6.1 Bioinformatics Reduces The Cost and Duration of Drug Discovery Process

6 By Product (Page No. – 83)
6.1 Introduction
6.2 Instruments
6.2.1 The Demand for Automated and Easy-to-Use Systems On A Rise
6.3 Consumables/Reagents
6.3.1 Assay Kits to Drive The HTS Market
6.4 Software & Services
6.4.1 Outsourcing to Drive The HTS Services Market

7 By Application (Page No. – 91)
7.1 Introduction
7.2 Target Identification
7.2.1 Target Identification Segment Occupies The Largest Share of HTS Applications Market
7.3 Primary Screening
7.3.1 Primary Screening is The Second Largest HTS Applications Market
7.4 Toxicology
7.4.1 Recent Advancements Present Significant Opportunities for Toxicity Testing
7.5 Stem Cell Biology
7.5.1 Stem Cells Provide Significant Advantages to HTS Technology
7.6 Other Applications

8 By End Users (Page No. – 102)
8.1 Introduction
8.2 Pharmaceutical & Biotechnology Industry
8.2.1 Pharmaceutical Companies Are The Biggest End-Users for HTS
8.3 Academic & Government Institutes
8.3.1 Open Innovation to Drive The HTS Market in Government Sector
8.4 Contract Research Organizations (Cro)
8.4.1 Emerging Countries to Drive The HTS Market for Cro
8.5 Other Industries (Hospitals/Clinics, Agriculture, Environmental Labs)

9 Geographic Analysis (Page No. – 113)
9.1 Introduction
9.2 North America
9.2.1 Rising Investments By Drug Discovery Companies to Drive The North American HTS Market
9.2.2 Collaborations Between Companies and Academic Institutes On A Rise
9.3 Europe
9.3.1 Public-Private Partnerships to Goad The European HTS Market
9.4 Asia
9.4.1 Government Initiatives Provide Scope for Growth of HTS Market in Asia
9.5 Rest of The World (ROW)

10 Competitive Landscape (Page No. – 161)
10.1 Introduction
10.1.1 New Product Launch, The Key Growth Strategy Adopted By HTS Players
10.1.2 New Product Launch
10.1.3 Agreements, Partnerships, and Collaborations
10.1.4 Mergers & Acquisitions
10.1.5 Expansions
10.1.6 Other Developments

11 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 170)
11.1 Agilent Technologies, Inc.
11.2 Aurora Biomed
11.3 Axxam Spa
11.4 Beckman Coulter, Inc. (A Subsidiary of Danaher)
11.5 Bio-Rad Laboratories
11.6 Biofocus Dpi Ltd.
11.7 Intellicyt Corporation
11.8 Luminex Corporation
11.9 Perkinelmer, Inc.
11.10 Sigma Aldrich Corporation
11.11 Tecan Group Ltd.
11.12 Thermo Fisher Scientific, Inc.

*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.

Appendix (Page No. – 232)